India Asthma Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

India Asthma Market Overview

Asthma places a continuing burden on respiratory health in India, where environmental exposures, urban air pollution, and variations in healthcare access can complicate disease management. Patients require timely diagnosis, appropriate medication, and sustained follow-up to reduce symptoms and prevent severe exacerbations. The market was valued at USD 1.16 Billion in 2025. The market growth is shaped by a large patient population, expanding healthcare infrastructure, and demand for affordable respiratory treatments. Inhaled corticosteroids, bronchodilators, and combination therapies remain important treatment options. Greater awareness, improvements in diagnostic capabilities, and evolving access to specialist care may support market expansion, while biologic therapies offer additional options for selected patients with severe, uncontrolled asthma.

India Asthma Market Growth Analysis and Key Influencers

India Asthma Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

India Asthma Market Growth Drivers

Increasing Asthma Awareness and Patient-Centric Initiatives to Support Market Expansion

The growing awareness of asthma and the importance of appropriate inhalation therapy is supporting the expansion of the market. Pharmaceutical companies are increasingly implementing patient awareness initiatives to address misconceptions, encourage timely screening, and improve disease management. For instance, in October 2026, Cipla brought its Berok Zindagi campaign through immersive inhaler installations during Durga Puja celebrations in Kolkata. The initiative also provided free digital lung health assessments through its Breathefree platform, reinforcing the importance of asthma awareness and appropriate inhalation therapy. Such initiatives can encourage greater treatment awareness and support market development.

India Asthma Market Restraints

Challenges in Accessing Appropriate Inhalation Therapy May Limit Market Value

Limited accessibility to appropriate inhalation devices and gaps in respiratory treatment awareness can constrain market development. The availability of effective inhalation therapies does not always ensure adequate treatment access, particularly when patients face difficulties obtaining suitable devices or maintaining treatment adherence. Such challenges can restrict the effective management of asthma and limit the adoption of advanced inhalation products. Addressing accessibility gaps and strengthening patient education remain important for improving treatment penetration.

India Asthma Market Opportunities

Advancements in Combination Therapies to Strengthen Treatment Options

The development of advanced combination therapies presents potential for expanding treatment options for patients with inadequately controlled asthma. Fixed-dose combinations integrating multiple therapeutic agents can support improved symptom management and provide convenient dosing options. Lupin introduced DIFIZMA®, a triple-drug combination of Indacaterol, Glycopyrronium, and Mometasone, in January 2023. The product was developed for inadequately controlled asthma and offered a once-daily dosing regimen. Such pharmaceutical innovations can address unmet treatment needs and support the development of the market.

India Asthma Market Trends

Some of the notable trends in the market include AI-powered screening solutions and technology-enabled respiratory healthcare.

Rising Adoption of AI-Powered Screening Technologies to Enhance Market Development

The increasing integration of artificial intelligence into respiratory screening is improving the accessibility and convenience of preliminary asthma assessments. Digital tools can help identify individuals who may require further clinical evaluation and encourage timely medical intervention. For instance, in January 2025, Cipla introduced CipAir®, an AI-powered mobile application for preliminary asthma screening in India. The application analyzes acoustic patterns from exhalation sounds to assess the likelihood of asthma and encourage timely clinical evaluation.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

India Asthma Market Share

Inhaled Route of Administration to Maintain a Leading Position in the Market

The market is segmented by route of administration into inhaled, oral, injectable, and other routes. Among these, the inhaled segment is expected to lead the market, supported by the direct delivery of medication to the lungs and the development of advanced inhalation devices. For instance, in May 2022, Alkem Laboratories launched Innohaler, a dry powder inhalation (DPI) device for asthma and chronic obstructive pulmonary disease (COPD) patients. The launch aimed to address accessibility gaps and improve drug delivery to the lungs. Such developments are expected to strengthen the adoption of inhaled therapies and support market growth.

Leading Players in the India Asthma Market

India Asthma Market Segmentation

Key Questions Answered in the India Asthma Market Report

• What was the India asthma market value in 2025?
• What is the India asthma market forecast outlook for 2026-2035?
• What are the major factors aiding the India asthma market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major asthma market trends?
• Which diseases severity is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which age group is likely to dominate the market segment?
• Which distribution channel is anticipated to lead the market segment?
• Who are the key players involved in the India asthma market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews with pulmonologists, respiratory medicine specialists, allergists, hospital procurement managers, and pharmaceutical industry representatives across India to assess treatment preferences, prescribing patterns, patient access, and emerging therapeutic requirements.
• Secondary Research: Peer-reviewed publications from The Lancet Respiratory Medicine and the Indian Journal of Chest Diseases and Allied Sciences; clinical guidelines from the Global Initiative for Asthma (GINA); epidemiological data from the World Health Organization (WHO), Indian Council of Medical Research (ICMR), and Global Burden of Disease (GBD) study; clinical trial records from ClinicalTrials.gov; and company websites for product portfolios, launches, and strategic developments.
• Validation: Quantitative estimates are triangulated through top-down and bottom-up market modeling and validated through expert feedback to ensure consistency and reliability.